Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime
Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime
| Release | Change | Old | New |
|---|---|---|---|
| July 2026 | Fee ↑ | $182.0 | $186.75 |
| November 2025 | Listed | — | $182.0 |
Data sourced from Australian Government publications · Not an official government service